Using engineered cells to treat arthritis through artificial signaling
Engineered cells as agents of arthritis therapy governed by artificial signaling
This study is exploring a new way to help people with osteoarthritis by creating special cells that can target and treat the damaged areas in their joints, aiming to reduce pain and help heal cartilage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10990815 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating osteoarthritis (OA) by engineering cells that can respond to specific signals in the joint environment. The goal is to create cells that can deliver therapeutic agents directly where they are needed, promoting cartilage regeneration and reducing inflammation. By utilizing advanced synthetic biology techniques, the project aims to develop a system that allows these cells to act as programmable agents, responding to the unique characteristics of joint degeneration. This could potentially lead to more effective treatments for patients suffering from OA.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with osteoarthritis who are experiencing joint degeneration and inflammation.
Not a fit: Patients with osteoarthritis who are not experiencing significant joint degeneration or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, disease-modifying therapy for osteoarthritis, reducing the need for surgery and improving patient quality of life.
How similar studies have performed: While the approach of using engineered cells in regenerative medicine is gaining traction, this specific application in osteoarthritis treatment is relatively novel and has not been extensively tested.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Brunger, Jonathan Matthew — Vanderbilt University
- Study coordinator: Brunger, Jonathan Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.